StudyFinder
Search Results
1 Study Matches
Site for Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma
Determine the maximum tolerated dose or maximum administered dose of MEDI5752 combined with axitinib Assess the safety and tolerability of MEDI5752 combined with axitinib Assess the antitumor activity of MEDI5752 combined with axitinib
The study will consist of 3 periods: screening, study treatment, and follow-up. You are expected to keep all of your study appointments and complete all study procedures.
$75 Per visit
All
18 year(s) or older
NCT04522323
SITE00000858
Inclusion Criteria:
Body weight > 35 kgHistologically or cytologically proven advanced RCC
Advanced RCC not previously treated in that setting
Must have at least 1 measurable lesion according to RECIST v1.1
Life expectancy ≥ 12 weeks
Exclusion Criteria:
Previous treatment with axitinibPrevious treatment with mTOR inhibitors, PD-1, PD-L1, or CTLA-4 inhibitors for RCC
History of active primary immunodeficiency
History of organ transplant
Cancer